Skip to content Skip to footer
Viewpoints_Dr. Volker Knappertz

Dr. Volker Knappertz, EVP R&D, Aurinia Shares Insights on LUPKYNIS MAA from EMA

Shots:Volker spoke about the granting of marketing authorization by EC to treat adults with active lupus nephritis.The approval was based on the results of the P-III AURORA study Volker also talked about the collaboration between Aurinia and Otsuka Pharmaceutical for the development and commercialization of LUPKYNISThe interview gives an understanding of how Aurinia…

Read more

Viewpoints_Neil Solomons

PharmaShots Interview: Aurinia’s Neil Solomons Shares Insights on the Lupkynis

In an interview with PharmaShots, Neil Solomons, Co-founder and Chief Medical Officer of Aurinia shared his views on the data of Lupkynis (voclosporin) presented at the National Kidney Foundation 2021 Spring Clinical Meetings.Shots:New data analysis from the AURORA and AURA clinical studies shows that Aurinia's therapy demonstrated efficacy across all LN biopsy classes. These data show that treatment…

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]